Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Neoplasms 6Breast Neoplasms 5Myeloproliferative Disorders 3Melanoma 3Lung Neoplasms 3Triple Negative Breast Neoplasms 2Skin Neoplasms 2Leukemia, Myeloid, Acute 2Head and Neck Neoplasms 2von Hippel-Lindau Disease 1Thrombosis 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Rectal Neoplasms 1Pyruvate Kinase Deficiency of Red Cells 1Precancerous Conditions 1Pancreatic Cyst 1Neuroendocrine Tumors 1Neoplasm, Residual 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Myelitis, Transverse 1Myasthenia Gravis 1Multiple Sclerosis 1Metastatic Castration-resistant Prostate Cancer 1Marijuana Abuse 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1

Interventions

pertuzumab 3Trastuzumab 3Docetaxel 2tucatinib 1atezolizumab 1Paclitaxel 1Neoadjuvant Therapy 1Genetic Testing 1Capecitabine 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2-positive Breast Cancer × Blood Specimen Collection × 30 days × Clear all
NCT04638725 2026-06-04

SIGHER

Centre Paul Strauss

Recruiting
9,000 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡